@article{e3c13c54b37a44b0a265c30ba5133340,
title = "Intravitreal Bevacizumab for Choroidal Neovascularization in Ocular Histoplasmosis",
abstract = "Purpose: To define the role of intravitreal bevacizumab in individuals with choroidal neovascularization (CNV) resulting from Ocular Histoplasmosis syndrome (OHS). Design: Retrospective chart review of a surgical therapy. Methods: We reviewed the course of 28 eyes of 28 patients who underwent intravitreal injection of bevacizumab for treatment of CNV secondary to OHS. Outcome was measured by pretreatment and posttreatment visual acuity (VA). Results: The average pretreatment logarithm of the minimum angle of resolution (logMAR) VA was 0.65 (Snellen equivalent of 20/88). Mean follow-up was 22.43 weeks with an average of 1.8 intravitreal injections. Average final logMAR VA was 0.43 (Snellen equivalent of 20/54). Twenty eyes (71%) experienced an increase in central VA, whereas four eyes (14%) were unchanged and four eyes (14%) experienced a decrease in vision. Conclusions: Intravitreal bevacizumab may improve or stabilize VA in a significant majority of patients with neovascular complications of OHS (24 eyes [85.7%] in our study population).",
author = "Ramin Schadlu and Blinder, {Kevin J.} and Shah, {Gaurav K.} and Holekamp, {Nancy M.} and Thomas, {Matthew A.} and Grand, {M. Gilbert} and Engelbrecht, {Nicholas E.} and Apte, {Rajendra S.} and Joseph, {Daniel P.} and Prasad, {Anita G.} and Smith, {Bradley T.} and Arsham Sheybani",
note = "Funding Information: The authors indicate no financial support or financial conflict of interest. Dr Blinder is part of the speaker bureau for Genentech and Novartis. Dr Shah serves on the Novartis Ad Board. Dr Holekamp serves as a consultant to Genentech and Alcon and she has received honoraria as a speaker for Genentech. Dr Apte has been a consultant for, has stock ownership in, has received lecture fees from, and has received grant support from Genentech, Inc. Dr Apte also has received grants from Eyetech, NIH, AFAR, and the Reeves Foundation. Involved in design and conduct of study (R.S., K.J.B., G.K.S.); collection, management, analysis, and interpretation of data (R.S., A.G.P., A.S.); and preparation, review, or approval of manuscript (R.S., K.J.B., G.K.S., N.M.H., M.A.T., M.M.G., N.E.E., R.J.A., D.P.J., A.G.P., B.T.S., A.S.). Institutional review board approval was obtained for this retrospective interventional case series from the Human Research Protection Office, Washington University, St Louis, Missouri. The study was performed under HIPAA guidelines. ",
year = "2008",
month = may,
doi = "10.1016/j.ajo.2007.12.030",
language = "English",
volume = "145",
pages = "875--878.e2",
journal = "American journal of ophthalmology",
issn = "0002-9394",
number = "5",
}